Objectives For child health randomized controlled trials (RCTs) published in 2012, we aimed to describe design and reporting characteristics and evaluate changes since 2007; assess the association between trial design and registration and risk of bias (RoB); and assess the association between RoB and effect size.
R
andomized controlled trials (RCTs) provide the best evidence to guide clinical practice when carried out appropriately. 1 Conversely, RCTs that are poorly conducted may yield biased estimates of treatment effects, 1,2 potentially leading to misinformed clinical decisions that could pose harm. 3 Especially for pediatric populations, where the quantity of relevant data lags behind that of adults, 4 there exists a need for well-conducted and reported RCTs. A review of a random sample (n = 300) of child health RCTs published in 2007 by our group 5 revealed that 92% were rated high or unclear risk of bias (RoB) based on Cochrane standards. 6 Though registered RCTs yielded superior Jadad scores 7 and lower RoB compared with those that were not registered, registration was declared in only 12% of publications. 5 Since the time of our review, substantial effort has been applied to improving the conduct and reporting of health research. For example, the Cochrane RoB tool, which facilitates the appraisal of systematic error in RCTs based on their conduct and reporting qualities, was only in its infancy at that time. 6 The Enhancing the Quality and Transparency of Health Research Network, 8 which supports the development, dissemination, and implementation of robust reporting guidelines CONSORT [11] [12] [13] [14] [15] adherence to the CONSORT checklist as a condition of publication is being adopted by an increasing number of journals. 16 Specific to pediatric health research, Standards for Research in Child Health was founded in 2009 with the mission of improving the design, conduct, and reporting of RCTs through the development and dissemination of evidencebased standards. 3, [17] [18] [19] [20] [21] [22] Moreover, a number of international pediatric trial networks have been established since the early 2000s to improve infrastructure and research capacity. 23 In light of these developments, we sought to investigate the conduct and reporting of child health RCTs published in 2012, 5 years following our 2007 analysis. 5 Specifically, for a random sample of 300 child health RCTs, we aimed to describe their design and reporting characteristics, including RoB; evaluate changes in trial design and reporting characteristics from 2007 to 2012; assess the association between trial design and reporting characteristics, and trial registration and RoB, respectively; and assess the association between RoB and magnitude of effect for the primary outcome.
Methods
On November 4, 2013, we searched the Cochrane Central Register of Controlled Trials for RCTs published in 2012 using pediatric subject headings and keywords (Appendix 1; available at www.jpeds.com). The search was modeled from that used to identify the 2007 sample (searched October 7, 2009 ). 5 Cochrane Central Register of Controlled Trials includes randomized and quasi-randomized controlled trials indexed in MEDLINE and EMBASE, hand-searched results, gray literature sources, and Cochrane Review Groups Specialized Registers of trials. 24 The search yielded 2296 unique records, which we uploaded to EndNote (Clarivate Analytics, Philadelphia, Pennsylvania) reference management software. From EndNote, we transferred the records (ordered alphabetically by author) to a Microsoft Office Excel (IBM Corporation, Armonk, New York) workbook, with each record allocated to an individual row. To order the records randomly, we allocated a number to each record using Excel's random number generator (ie, the RAND function), which returns a random number between 0 and 1. We then reordered the records from smallest to largest to yield a randomly ordered list.
To ensure comparability to our 2007 findings, 5 we employed identical selection criteria. A single researcher screened the records by title and abstract and selected RCTs that reported on outcomes of participants ≤21 years of age. We did not restrict the sample by language, condition, intervention, nature of the comparator, nor outcome type. To be consistent with the 2007 sample size, we included the first 300 (13%) eligible records from the randomly ordered list (Appendix 2; available at www.jpeds.com).
We used the data extraction form from our 2007 study, 5 with additional items added following consultation with clinical and methodological experts (Appendix 3; available at www.jpeds.com). From each record we extracted characteristics of the publication, study design, intervention, trial conduct, study sample, sample size, data monitoring committee (DMC) and follow-up, outcomes and conclusions, methodological quality, and registration and protocol. We extracted data for the primary outcome. When not specified, we inferred the primary outcome as the (1) objective outcome, (2) outcome used to calculate the sample size, or (3) first outcome reported in the results. All extracted data were verified by a second researcher to identify and resolve errors.
When available, we used the trial register, published protocol, and/or companion article(s) to supplement data extraction. If not cited in the publication, we searched for trial registers in the International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/), the ISRCTN Registry (http://www.isrctn.com/), and via Google (https:// www.google.ca/). We used protocols or companion articles only when cited in the publications.
We used the 2010 Cochrane RoB tool 25 to assess RoB for the primary outcome among 7 domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other bias. We assessed each domain as low, unclear, or high risk following Cochrane procedures 6 and internal decision rules (Appendix 4; available at www.jpeds.com). Overall RoB was determined as follows: low when all domains were assessed as low; unclear when at least 1 domain was assessed as unclear and no domains were assessed as high; and high if any domain was assessed as high. 6 Two reviewers assessed each record and discussed the judgments until consensus was reached or a third party provided arbitration.
computed the standardized mean difference (SMD) for studies where the primary outcome was continuous. The mean difference, or difference in means, is a statistic that measures the absolute difference between the mean outcome value in 2 groups (eg, intervention group and control group) in a trial. 6 This is known as the effect size. In this study, the contributing trials reported various outcomes that were measured in different ways (eg, using different scales), so we used the SMD. The SMD standardizes the results of the contributing trials by expressing the size of the intervention effect for each trial relative to its variability. 6 This yields standardized effects that can be pooled. 6 For studies where the primary outcome was dichotomous (eg, events), we calculated effect size using the methods described by Borenstein et al. 26 Effect sizes were pooled using DerSimonian-Laird random effects for each of the 3 levels of RoB (low, unclear, high). We assessed differences across levels of RoB using the c 2 test for subgroups in meta-analysis. RCTs were published in specialty pediatric journals (18.3% vs 23.3%) and more were published in general medical (9.0% vs 6.3%) and "other" journals (ie, not medical or health journals, such as Computers in Human Behavior, PLoS One, and Cell Biochemistry and Function) (5.3% vs 0.3%) (P = .001). More 2012 RCTs used cluster designs (10.7% vs 0%) and fewer used parallel designs (80.7% vs 89.7%) (P < .001). In the 2012 sample, there were more superiority trials (93.0% vs 82.7%) (P < .001) and fewer RCTs of pharmacologic interventions (ie, drugs or vaccines) (33% vs 45.7%) (P < .001). Fewer 2012 RCTs were placebo controlled (17.3% vs 30.0%) (P < .001), and fewer were single center (46.7% vs 59.7%) (P = .003). Compared with 2007, 5 more 2012 RCTs reported the funding source (80.3% vs 64.7%) (P < .001), less were industrysponsored (20.7% vs 34.5%) (P = .002), and more reported a DMC (18.7% vs 4.7%) (P < .001). More 2012 RCTs specified the primary outcome (62.3% vs 40.7%) (P < .001), and reported findings that favored the experimental intervention (93.4% vs 82.2%) (P = .007). More 2012 RCTs were registered (46.3% vs 23.0%) (P < .001).
Compared with 2007, 5 more 2012 RCTs were rated low (38.3% vs 25.0%) and less were rated unclear (59.7% vs 72.3%) risk for allocation concealment (P < .001) ( Table II) . Fewer 2012 RCTs were rated low (33.3% vs 50.3%) and more were rated high (30.0% vs 13.7%) risk for blinding of participants and personnel (P < .001). More 2012 RCTs were rated low risk for blinding of outcome assessors (68.3% vs 50.3%) (P < .001) and other bias (77.3% vs 35.3%) (P < .001). Fewer were rated low risk for selective reporting (32.0% vs 82.0%) (P < .001). Though a similar proportion of 2012 RCTs were rated low risk for overall RoB (7.3%) compared with 2007 (7.7%), a greater proportion were rated unclear (45.0% vs 33.0%) and less were rated high (47.7% vs 59.3%) (P = .030). Table III shows the characteristics of the 2012 RCTs stratified by trial registration and overall RoB. Registration varied significantly by continent. For example, 58.1% of RCTs from North America were registered compared with 22.7% of those from Asia (P < .001). More RCTs that specified the funding source were registered (54.8%) compared with those that did not (11.9%) (P < .001). More RCTs that reported a sample size calculation were registered (63.2%) compared with those that did not (28.3%) (P < .001). More RCTs that reported a DMC were registered (96.4%) compared with those that did not (35.1%) (P < .001). More RCTs that specified the primary outcome were registered (58.8%) compared with those that ¶Other study designs included pilot trials and mixed designs (eg, equivalence and noninferiority). **Alternative therapeutic interventions included complementary and alternative treatments (eg, yoga, music therapy). † †Other interventions included prevention and screening, rehabilitation or psychosocial, surgery or radiotherapy, and communication, organizational, or educational programs. ‡ ‡Other conditions included injuries, poisoning, external causes of morbidity and mortality, conditions of the eye and adnexa, and digestive disorders, among others. 27 Conditions were categorized to be comparable with the 2007 data. § §Data from 2007 and 2012 are not directly comparable because in 2012, only trials that reported a statistically significant primary outcome were assessed. In 2007, any trial that reported a statistically significant outcome (primary or otherwise) was assessed. ¶ ¶Includes trial registration cited in the publication (n = 130) and registers located via an online search (n = 9). 25 Though identical values from 2007 have been reported for both blinding domains, it is acknowledged that these are not directly comparable to the 2012 data. §In 2007, selective reporting was assessed by comparing the outcomes reported to those in the Methods section of the publication. In 2012, selective reporting was assessed by comparing the outcomes reported in the publication to those reported in the registry or protocol. Unregistered trials and those without protocols were assessed as unclear risk for this domain. ¶In 2007, other bias included the funding source (ie, trials funded by industry would be rated at high risk of bias). In 2012, the funding source was not considered in assessment of risk of bias.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 193 did not (25.7%) (P < .001). More RCTs that planned to collect data on adverse events were registered (63.4%) compared with those that did not (32.5%) (P < .001), and more that reported at least 1 adverse event were registered (61.9%) compared with those that did not (35.1%) (P < .001). More RCTs at low risk of bias were registered (90.9%) compared with those at unclear (42.2%) or high risk (43.4%) (P = .009).
More RCTs that reported a sample size calculation were at low RoB (12.9%) compared with those that did not (1.4%) (P < .001). More RCTs that reported a DMC were at low RoB (21.8%) compared with those that did not (4.1%) (P < .001). More RCTs that specified the primary outcome were at low RoB (9.6%) compared with those that did not (3.5%) (P = .002), and more RCTs that reported no significant outcomes were at low RoB (12.7%) compared with those that reported at least 1 significant outcome (6.1%) (P = .008). More RCTs that planned to collect adverse events data were at low RoB (11.9%) compared with those that did not (3.6%) (P < .001), and more RCTs that reported at least 1 adverse event were at low RoB (11.1%) compared with those that did not (4.6%) (P < .001). More RCTs that reported conclusions not in favor of the experimental intervention were at low RoB (15.8%) compared with those that reported neutral conclusions (9.5%) or those in favor of the intervention (5.1%) (P = .030). Registered RCTs were more likely to be at low RoB (14.4%) compared with nonregistered ones (1.2%) (P = .009). .027 n/a n/a n/a n/a § For 203 RCTs where sufficient data were reported (68 with dichotomous and 135 with continuous data), the absolute effect size for those at low RoB was 0.70 (95% CI 0.28, 1.13), compared with 0.46 (0.37, 0.56) and 0.58 (0.42, 0.73) for RCTs at unclear and high RoB, respectively (Table IV) . There was no association between effect size and RoB.
Discussion
Our data indicate that the landscape of pediatric research is changing. Compared with 2007, the 2012 RCTs differed significantly with respect to many design characteristics. Notably, the 2012 sample included more cluster RCTs, which were absent in the 2007 sample. The 2012 sample also included more superiority trials, and fewer drug trials and placebo-controlled trials. Compared with 2007, in 2012 a significantly larger proportion of trials were multicenter. With respect to reporting, more 2012 RCTs reported the funding source, the presence of a DMC, and specified the primary outcome.
We also noted significant changes with respect to RoB. Some changes may be attributable to genuine differences in conduct, reporting, or trial design between samples. For some domains, changes are more likely attributable to how RoB was assessed. In 2007, we used an earlier version of the Cochrane RoB tool (Appendix 5; available at www.jpeds.com), precluding direct comparisons. In 2007, blinding was assessed as a single domain. Selective reporting was assessed by checking for consistency between the outcomes reported in the methods and results sections of the publication. In 2012, judging selective reporting required comparing the outcomes reported in the publication to those in the protocol. With respect to other sources of bias, in 2007 judging RoB included accounting for financial interests. In 2012, the funders were not considered in the judgment of risk in this domain.
Random sequence generation and allocation concealment were more consistently assessed at both time points. Stability or change in these domains is more likely attributable to characteristics of the conduct, reporting, or design of the RCTs. We observed no change over time with respect to random sequence generation. Akin to 2007, approximately one-half of 2012 RCTs were rated unclear risk, likely because of reporting shortfalls (eg, stating that the participants were "randomized" without specifying how). With respect to allocation concealment, from 2007 to 2012 we observed an increase in the proportion of RCTs rated low risk, however nearly twothirds of RCTs remained at high or unclear risk. Similarly, in 2010 Crocetti et al 28 reported that 41% and 57% of pediatric trials published in high impact journals were at high or unclear RoB for random sequence generation and allocation concealment, respectively.
Insufficient blinding of participants and personnel was present in two-thirds of the 2012 RCTs. Most RCTs rated high risk evaluated rehabilitation or psychosocial interventions, and communication, organizational, or educational programs. In these types of interventions, blinding of participants and personnel is often infeasible. 29 Blinding of the outcome assessors is more often realistic, and most 2012 RCTs were rated low risk on this domain. Selective reporting was present in twothirds of the 2012 RCTs. In 2004, the International Committee of Medical Journal Editors published a statement supporting comprehensive registration of trials in an effort to improve reporting, and 11 of its member journals adopted a registration policy. 30 In our sample, registration was associated with more complete reporting of the funding source, sample size calculation, a priori primary outcome(s), and adverse events. Selective reporting, however, was observed even among registered trials.
Selective reporting introduces biases that often favor a statistically significant primary outcome. 31, 32 In our study, more registered than unregistered trials were at low RoB. Using the Cochrane RoB tool, trial registration or a published protocol are necessary components of judging the selective reporting domain. When these are unavailable, the potential for bias due to selective reporting is at least unclear, and accordingly, overall RoB cannot be low. In the study by Crocetti et al, 28 registered trials were less likely to be at high risk of bias for random sequence generation. Similarly, registered trials in our study performed better on the random sequence generation, allocation concealment, blinding, and selective reporting domains. Although registered trials made up over 90% of those judged low overall RoB in this study, still 86% of registered trials were at high or unclear RoB. Similarly, in a sample of pediatric trials published in 2013, Rosati et al 32 noted serious discrepancies between the trial registry and the published study, including selective outcome reporting. Registration is thus necessary, but not sufficient alone to eliminate threats to the internal validity of the results of child health trials. [31] [32] [33] [34] [35] We identified a number of shortfalls in the reporting (and potentially conduct) of child health RCTs that should be addressed. Random sequence generation and allocation concealment are always feasible in RCTs. 29 These were not often carried out and/or reported appropriately, potentially resulting in exaggerated treatment effects. 29, 36, 37 Signs of selective reporting, identified as a common issue in RCTs published in leading medical journals, 38 was prevalent in our sample. Clear guidance exists to support the complete and transparent reporting of RCTs, 1 however, these are inadequately adopted and adhered to.
14 Journals that endorse CONSORT publish RCTs that are more completely reported compared with those that do not. 16 Nevertheless, even CONSORT-endorsing journals do not consistently enforce reporting issues, 39 and support to guide peer reviewers in assessing reporting quality is often inadequate. 40 As indicated by our data, registered child health RCTs are more likely to be at low RoB and to be more completely reported.
Steps toward improvement would include measures to increase trialists' awareness and application of reporting guidance, and the prospective 41 registration of all RCTs. Strategies that translate the guidance for complete and transparent reporting into clear and concise messages for trialists may be required. Enforcement of CONSORT by a greater proportion of journals, including guidance for peer reviewers on how to identify reporting inadequacies, may help to improve the quality of published child health RCTs. The adoption of trial registration as a requirement for publication by a greater proportion of journals may also help to improve transparency and reduce bias. As the landscape of pediatric health research continues to evolve, quality should be continuously evaluated to identify trends and areas for improvement.
The 2007 sample differed from the 2012 one with respect to many design features, which may have impacted RoB. To maximize comparability, we employed a similar search strategy and identical sampling scheme in both years. Assessment of RoB is inherently subjective, and concordance of assessments by independent author groups are moderate, at best. 42, 43 To maximize consistency, MPD, who completed the 2007 assessments, trained the 2012 reviewers and standard decision rules were used. In 2007 an earlier version of the RoB tool was used, precluding direct comparisons for some domains. Because the majority of the variables investigated were related to reporting, our findings may not account completely for trial conduct.
The data presented herein represent only a small subset of those collected as part of this study. Because of resource and staffing constraints, the timelines for data collection and verification, statistical analyses, and manuscript writing were relatively lengthy, accounting for use of a sample from 2012. In subsequent updates to this work, more focused data collection (eg, a smaller subset of high-priority variables) will allow for timelier reporting of the findings.
Though improvements with respect to some RoB domains were observed, others were unchanged and the majority of RCTs remained at unclear or high overall RoB. Although clear and transparent reporting is important, methodological rigor in the design and conduct of trials is critical to ensuring relevant and valid results. This study has identified a number of key design elements that need further improvement. Optimizing the design, conduct, and reporting of trials will reduce research waste in a field where quality findings to support clinical decision-making are limited. The healthy options for nutrition environments in schools (Healthy ONES) group randomized trial: using implementation models to change nutrition policy and environments in low income schools 
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The 
General Instructions for REDCap
-To select the record you want to work on, click the drop-down arrow beside the record list (probably Incomplete Records unless you want to make changes to a record that you have designated Unverified) and scroll down to select the record that matches the reference ID you are working on. You can also type the record number in the "Enter a new or existing Record ID" space and then click the matching record that pops up -note that this is probably faster but can only be done from the "Publication Characteristics" form.
-At the bottom of every page within the data extraction form, there are buttons to "Save Record," "Save and Continue," and "Save and go to Next Form." "Save Record" will save the page you are currently on and take you back to the main menu. "Save and Continue" will allow you to save your work and continue on the same page. "Save and go to Next Form" will save your work and take you to the next page in the data extraction form. REDCap times out after approximately 15 minutes of inactivity and will log you out of the program, so please save your work regularly as you go.
-At the bottom of every page, there is a drop down menu where you can indicate whether the page is "Incomplete," "Unverified," or "Complete." As you complete each page, please change this from "Incomplete" to "Complete." If you have an outstanding question, mark it as "Unverified." Please also let me know as questions arise.
-At the bottom of each page, there is a text box for comments. If you have a comment or question about any of the fields as they pertain to the study you are extracting data from, leave a response here, and the data can be checked.
-To navigate back and forth through the data extraction form, use the list of each of the pages found on the left-hand side of the screen.
Data Extraction Guidelines *USE ALL AVAILABLE INFORMATION (INCLUDING PROTOCOLS OR COMPANION ARTICLES REFERENCED IN THE PUBLICATION, AND RECORD OF TRIAL REGISTRATION) TO COMPLETE DATA EXTRACTION, RISK OF BIAS, AND CONSORT ASSESSMENTS.
-We will include a MAXIMUM OF THREE sources per trial: 1. The trial identified as part of our sample; 2. The trial register, if available; and 3. EITHER the published protocol or methods document, if cited in our original study (first choice) OR the sentinel trial in the case of multiple publications, if cited in our original study (second choice).
When the trial included in our study sample references companion articles that are used to complete data extraction, please save a copy in Dropbox (Skyfall > Supplementary Articles). For quality assessment and data verification, please check Dropbox for any additional articles prior to starting.
Please note the differences in the use of 'no' and 'N/A.' Use 'no' when something hasn't been done when it could have been possible; use 'N/A' when it doesn't apply to that particular trial. For example, to report whether the treatment effect was reported by a subgroup other than age, use 'no' if there is another subgroup, but the treatment effect hasn't been reported accordingly, and use 'N/A' if there are no other subgroups. Compensation: participants are paid a modest amount for their time/effort. Appreciation: a small token gift given at the end of the study, usually not known beforehand. Payment: typically known before study participation and used as a strategy to enhance recruitment.
*Use "families" only if specified as such in the publication, with no information provided on whether the incentives were meant for the parents or child.
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The Select all that apply.
In the case of selection from a dental clinic, report "Doctor's office."
What primary diagnostic category was involved in the study? □Infectious and parasitic diseases □Neoplasms □Blood, blood forming organs, Select the primary diagnostic category of the study using the ICD-10 classification system. If the outcome data is not presented as described above, use the Effect Size Calculator spreadsheet provided to calculate the SMD and SE.
Only select "other" if the data does not fit into any categories provided in the spreadsheet and you would like to enter a comment.
Use "N/A" if the data reported fits into the standard n/mean/SD categories for continuous outcomes and n/# of events for dichotomous outcomes.
To use the spreadsheet:
1. Fill out any available information only in the sections highlighted in yellow. Any other cells in the spreadsheet will automatically populate with the relevant calculations. 2. Scrolling down on the sheet, use the section labelled "Standardized Mean Difference Computations" to obtain the results to report. Take the calculated value for SMD and SE (SMD) and enter into the DE form. If there are values for multiple sections, use the one closer to the top of the list (e.g., take the value under "based on reported treatment difference" over "based on reported CFB in both treatment and control"). 3. If there are more than two study arms, extract data for one treatment and one control group, based on (in order): a. the authors' specified intent; or b. the control group with the least intervention (e.g., placebo, rather than a low dose) and the treatment group with the most intervention (e.g., a high dose rather than a low dose 
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ROB Decision Criteria Low
No blinding or incomplete blinding, but the outcome is unlikely to be influenced by lack of blinding. Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken. Description of "double-blinding" with specification that the participants and study personnel are blinded. Description of the use of "double-dummy" or "matched placebo." Unclear Insufficient information to permit judgment. The study did not address blinding.
High
No blinding or incomplete blinding and the outcome is likely to be influenced. Blinding attempted, but likely that it could have been broken and the outcome is likely to be influenced.
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RISK OF BIAS FOR CHILDREN IN TRIALS -007
Guidelines and Decision Rules for Risk of Bias Assessments
*Use these decision rules in addition to the guidelines outlined in the Cochrane criteria (attached).
Sequence generation:
-If blocked randomization, permutation, or stratification is specified, assume the randomization sequence was computer-generated and answer YES. -If the description only includes 'random', 'randomly generated', 'randomized', etc, do not assume additional details and answer UNCLEAR.
Allocation concealment:
-If the randomization is conducted by central telephone, pharmacy, etc, assume this is adequate and answer YES.
Blinding:
-Determine whether the blinding is likely to be broken, and whether the outcomes in unblinded studies are likely to be influenced by the lack of blinding. -If a study is described as "double-dummy", assume that this is appropriate and answer YES. If it is described as "double-blind" without further details, answer UNCLEAR.
Incomplete outcome data:
-Look for intention-to-treat analysis. If this was done appropriately, answer YES.
-If all participants were accounted for (i.e. no drop-outs or censored analysis conducted), answer YES. -If the numbers and reasons for withdrawal/drop-outs were described and comparable across groups (and ≤ approximately 10%), answer YES. -If there is greater than 10% drop-out, consider UNCLEAR or NO.
Selective outcome reporting:
-If the study protocol is available, compare the outcomes reported in the publication to those specified in the protocol. Answer YES if the outcomes in the two documents match. -If the study protocol is not available, compare the outcomes reported in the Methods and Results sections. Answer YES if these match.
Other sources of bias:
-Assess for baseline imbalances that could have biased the results (or were not accounted for).
-Assess for early stopping for benefit.
-Assess for appropriateness of cross-over design (e.g. inadequate wash-out period).
-Assess for inappropriate influence of funders that could have biased the results. If sponsor is acknowledged and there is a clear statement regarding no involvement of sponsor in trial conduct or data management/analysis, answer YES. If sponsor is acknowledged and no one from the sponsoring agency was an author, answer YES. If sponsor is acknowledged and someone from the sponsoring agency was an author, answer NO. If a drug/intervention is provided by industry, but the trial has no other inappropriate influence of funding, answer YES. If there is no mention of funding source, answer UNCLEAR. -Note any "other" sources of bias. *Minimization may be implemented without a random element, and this is considered to be equivalent to being random.
Criteria for the judgement of 'NO' (i.e. high risk of bias).
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example: Sequence generated by odd or even date of birth;
Sequence generated by some rule based on date (or day) of admission;
Sequence generated by some rule based on hospital or clinic record number.
Other non-random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non-random categorization of participants, Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).
Insufficient information to permit judgement of 'Yes' or 'No'. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement -for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
BLINDING OF PARTICIPANTS, PERSONNEL AND OUTCOME ASSESSORS
Was knowledge of the allocated interventions adequately prevented during the study? [Short form: Blinding?]
Criteria for a judgement of 'YES' (i.e. low risk of bias).
Any one of the following:
No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding;
Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.
No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding; Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken; Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias). Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;
Missing data have been imputed using appropriate methods.
Any one of the following:
Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;
For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization; Potentially inappropriate application of simple imputation.
Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).
Insufficient reporting of attrition/exclusions to permit judgement of 'Yes' or 'No' (e.g. number randomized not stated, no reasons for missing data provided);
The study did not address this outcome.
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